EyesOn Orca, Vertex, & Ipsen Clinical Data

This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

Ipsen revealed last week that its Dysport had met the objectives in two phase 3 trials for the prevention of both episodic and chronic migraines, marking a first for the neurotoxic market.

According to Ipsen, Dysport is the first botulinum toxin to also reveal positive phase 3 findings in episodic migraine, despite the FDA having approved AbbVie’s market-leading Botox to prevent headaches in patients with chronic migraine since 2010.

The readouts are from research conducted in Ipsen’s Beond program, which included 1,510 patients divided between C-Beond (chronic) and E-Beond (episodic). With a statistically significant decrease in monthly migraine days compared to placebo, both trials have achieved their main objectives.

According to Ipsen, these results put Dysport in a position to be a first-in-class treatment for a large migraine population. The business will examine all of the data and be ready to file with the FDA and other regulatory bodies.

Patients with episodic migraines make up a significantly larger patient group than those with chronic migraines. Patients who experience no more than 14 headache days per month, including at least six migraine days, are classified as having episodic migraine according to the E-Beond experiment. The 14-headache-day-per-month cutoff is a well recognised benchmark, while specific definitions of episodic vs. chronic migraine may differ.

Ipsen now has another platform to challenge Botox’s hegemony thanks to the clinical triumph. Last year, sales of the AbbVie blockbuster’s therapeutic and cosmetic indications were about $6.4 billion. In contrast, Dysport’s 2025 revenue from both fields was over $500 million, while Ipsen’s was $341 million.

Dysport was first approved by the FDA in 2009 for glabellar lines and cervical dystonia. It is also recommended for some individuals with spasticity.

Between 14% and 15% of people worldwide suffer from migraines, both episodic and chronic. Ipsen is developing a recombinant neurotoxic named corabotase (IPN10200) in phase 2, having previously advanced the asset into phase 3 in terms of aesthetics, in order to approach both types of the disease from a different perspective.

According to Ipsen’s September 2025 report, corabotase provided a considerably longer duration of impact than Dysport in the phase 2 Lantic research in aesthetics when it came to reaching a score of ‘none’ or ‘mild’ line severity at week 24.

A disagreement between Ipsen and Galderma, its longstanding commercialisation partner, also involved the more recent molecule. Prior to Ipsen’s move to end their 2014 R&D collaboration, the two businesses had a disagreement about who would oversee next-generation neuromodulator initiatives.

The International Chamber of Commerce’s arbitral tribunal ultimately ruled in favour of Ipsen in January 2026, enabling the French pharmaceutical company to end the R&D agreement and assume complete management of its clinical-stage toxin programs in the cosmetic industry. The two businesses’ commercialisation cooperation around Dysport was unaffected by the R&D legal controversy.

For more details: 

PharmaTell

PharmaTell

FiercePharma

Through the FDA’s Commissioner’s National Priority Voucher (CNPV) program, Vertex has obtained a label expansion that permits children as young as two years old to receive the gene therapy Casgevy for the one-time treatment of transfusion-dependent beta thalassaemia (TDT) or sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs).

CRISPR Therapeutics co-developed the ground-breaking treatment, which was already authorised for use in patients 12 years of age and older. According to the Boston-based company, the expansion allows 5,500 more children in the US to utilise Casgevy, providing those patients and their families with a chance to lower the risk of organ damage that may arise from either illness.

According to the business, early access to this therapy’s transformative potential would enable doctors and families to think about treatment before years of cumulative harm from these life-shortening conditions take effect.

Results from two ongoing phase 3 trials provide some evidence for the expansion. According to a different FDA approval announcement, all eight patients who were evaluable for effectiveness in one, which included 11 children with SCD aged 5 to 12, achieved the primary endpoint with no severe VOCs for at least 12 consecutive months.

Eight of the nine TDT patients who could be evaluated for efficacy in the other trial, which included 15 patients in the same age group, met the same threshold, with a median duration of transfusion independence of 20 months.

According to Vertex, the expansion of the indication down to two years of age was also based on clinical research findings in both indications and the known characteristics of Casgevy.

According to the business, the outstanding consistency of outcomes across age groups supports Casgevy’s ability to provide long-lasting, revolutionary advantages to people who have traditionally had few options.

The approval is part of the CNPV program, which was started by previous FDA commissioner Marty Makary, M.D., who resigned from the agency in May after a contentious stint.

The CNPV program was created to significantly reduce review times for specific goods and businesses that support the national interests of the United States.

When Casgevy was first licensed in 2023 for sickle cell disease (SCD), it was heralded as the first medication created with the ground-breaking CRISPR gene-editing technology, which won its creators a Nobel Prize in 2020 and has exciting promise to treat other illnesses for which there are now no medicines.

The FDA authorised Bluebird Bio’s SCD gene treatment Lyfgenia on the same day that it first approved Casgevy. Both treatments are gaining traction even though uptake has been sluggish, partly due to their relative costs of $2.2 million and $3.1 million.

With 64 patients receiving injections in 2025, including 30 in the fourth quarter, Casgevy’s sales totaled $116 million. Vertex reported $43 million in Casgevy sales throughout the first three months of this year. More than 500 patients have started using Casgevy since it was introduced to the market, according to the company’s report.

According to private Genetix Biotherapeutics, which does not disclose treatment sales, more than 150 patients finished the initial cell collection for Lyfgenia in 2025, and more than 100 received infusions. Private equity firms Carlyle and SK Capital founded Genetix following the sale of Bluebird last year. For patients with SCD and TDT who are 12 years of age or older, Lyfgenia is still approved.

For more details:

PharmaTell Studio

FDA News

With FDA approval for Tregzi, a novel tailored cell therapy for blood cancer patients in need of transplants, Orca Bio has entered the commercial market.

The FDA authorised Orca-T, an allogeneic regulatory T cell (Treg)-based immunotherapy, last week for use as a substitute stem cell transplant to increase longevity free of chronic graft versus host disease (GVHD) in people with haematological malignancies.

Tregzi is fundamentally a haematopoietic stem cell transplant (HSCT) graft that has been reengineered. In order to prevent GVHD, a common and frequently crippling transplant consequence, Tregzi reformulates the blood material to incorporate pure Tregs instead of directly infusing a patient with a mixture of stem and immune cells from a matched healthy donor. Additionally, it uses haematopoietic stem and progenitor cells to help patients rebuild their immune systems to fight cancer. Conventional T cells are then infused to eradicate any remaining cancer cells and hasten the healing process against infections.

The phase 3 Precision-T trial, which randomly assigned 187 patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome, and mixed-phenotype acute leukaemia to receive either Tregzi or unmanipulated allograft, served as the basis for the FDA’s approval. Additionally, GVHD prophylaxis was administered to all patients; tacrolimus alone was used for Tregzi, while methotrexate plus tacrolimus were given for control.

Compared to 38% of patients receiving standard transplants, 78% of patients receiving Tregzi were alive and free of chronic GVHD at one year, resulting in a 74% improvement in chronic GVHD-free survival.

In a single year, the incidence of moderate-to-severe chronic GVHD alone was 13% for Tregzi and 44% for control. Additionally, the total survival rate was 83% with an unedited transplant and 94% with the Orca medication.

The FDA’s initial planned decision date was extended by over three months before last week’s clearance. After requesting additional manufacturing-related data from Orca, the government took more time. According to the business, every cell therapy is produced differently, necessitating a two-way education campaign between the FDA and the sponsor, particularly about the manufacturing process.

Acknowledging the industry maxim that in cell therapies, the procedure is the product, Orca is now concentrating on providing patients with Tregzi in a dependable manner. Orca is dedicated to keeping a vein-to-vein timetable between gathering donor cells and having the finished product available at the hospital for infusion within 72 hours, even though Tregzi production is now centralised at a facility in Sacramento, California.

Tregzi circumvents the manufacturing failure problem that has beset current autologous CAR-T treatments, which rely on the patient’s own T cell fitness. In contrast, Tregzi uses more dependable, healthy donor cells. Orca anticipates maintaining the production failure rate at a single digit to a low single digit as a result. In order to have about 25 centers by the end of the year, the firm has strategically planned a production ramp and an onboarding ramp in addition to introducing Tregzi at a few treatment facilities, according to the company.

In order to satisfy growing demand and further shorten vein-to-vein times nationwide, the California company unveiled a new manufacturing plant in Princeton, New Jersey, a few days ago.

Tregzi is being charged at $428,000 by Orca as the wholesale acquisition fee. According to the company, it has set up reimbursement paths for both government and commercial programs and is dedicated to provide assistance to guarantee access for qualified patients.

Orca Bio is now one of the few privately held commercial pharmaceutical companies in the United States thanks to the FDA’s approval. The company announced $250 million in fresh funding from two recent funding rounds at the start of the year, including a series F that completed in December. The majority of those proceeds are intended to aid in the launch of Tregzi. Orca is well-capitalized for the launch of Tregzi, which is currently the company’s top priority.

For more details:

PharmaTell Studio

CancerNetwork